Gefitinib for Epidermal Growth Factor Receptor Activated Osteoarthritis Subpopulation Treatment | |
Sun, Heng1,2; Wu, Yan1,2,6; Pan, Zongyou1,2; Yu, Dongsheng1,2,7; Chen, Pengfei1,2; Zhang, Xiaoan1,2; Wu, Haoyu1,2; Zhang, Xiaolei1,2,8; An, Chengrui1,2; Chen, Yishan1,2 | |
刊名 | EBIOMEDICINE
![]() |
2018 | |
卷号 | 32期号:1页码:223-233 |
关键词 | Posttraumatic Osteoarthritis Rheumatic Conditions Lung Adenocarcinoma United-states Cartilage Autophagy Mouse Model Prevalence Disease |
ISSN号 | 2352-3964 |
DOI | 10.1016/j.ebiom.2018.06.002 |
文献子类 | Article |
英文摘要 | Osteoarthritis (OA) is a leading cause of physical disability among aging populations, with no available drugs able to efficiently restore the balance between cartilage matrix synthesis and degradation. Also, OA has not been accurately classified into subpopulations, hindering the development toward personalized precision medicine. In the present study, we identified a subpopulation of OA patients displaying high activation level of epidermal growth factor receptor (EGFR). With Col2a1-creER(T2); Egfr(f/f) mice, it was found that the activation of EGFR, indicated by EGFR phosphorylation (pEGFR), led to the destruction of joints. Excitingly, EGFR inhibition prohibited cartilage matrix degeneration and promoted cartilage regeneration. The Food and Drug Administration (FDA)-approved drug gefitinib could efficiently inhibit EGFR functions in OA joints and restore cartilage structure and function in the mouse model as well as the clinical case report. Overall, our findings suggested the concept of the EGFR activated OA subpopulation and illustrated the mechanism of EGFR signaling in regulating cartilage homeostasis. Gefitinib could be a promising disease-modifying drug for this OA subpopulation treatment. (C) 2018 The Authors. Published by Elsevier B.V. |
WOS研究方向 | Medicine, General & Internal ; Medicine, Research & Experimental |
语种 | 英语 |
WOS记录号 | WOS:000436312000027 |
内容类型 | 期刊论文 |
版本 | 出版稿 |
源URL | [http://202.127.25.143/handle/331003/3406] ![]() |
专题 | 生化所2018年发文 |
作者单位 | 1.Zhejiang Univ, Zhejiang Univ Univ Edinburgh Inst, Dr Li Dak Sum & Yip Yio Chin Ctr Stem Cell & Rege, Hangzhou 310058, Zhejiang, Peoples R China; 2.Key Lab Tissue Engn & Regenerat Med Zhejiang Prov, Hangzhou 310058, Zhejiang, Peoples R China; 3.Zhejiang Univ, Sch Med, Dept Sports Med, Hangzhou 310058, Zhejiang, Peoples R China; 4.Zhejiang Univ, Collaborat Innovat Ctr Diag & Treatment Infect Di, Affiliated Hosp 1, State Key Lab Diag & Treatment Infect Dis,Sch Med, Hangzhou 310058, Zhejiang, Peoples R China; 5.China Orthoped Regenerat Med Grp, Hangzhou 310058, Zhejiang, Peoples R China; 6.Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Orthopead, Hangzhou 310058, Zhejiang, Peoples R China; 7.Hangzhou Med Coll, Zhejiang Prov Peoples Hosp, Dept Orthoped, Hangzhou 310014, Zhejiang, Peoples R China; 8.Wenzhou Med Univ, Affiliated Hosp 2, Dept Orthopaed, Wenzhou 325035, Zhejiang, Peoples R China; 9.Chinese Acad Sci, Shanghai Inst Biochem & Cell Biol, CAS Ctr Excellence Mol Cell Sci, State Key Lab Cell Biol, Shanghai 200031, Peoples R China |
推荐引用方式 GB/T 7714 | Sun, Heng,Wu, Yan,Pan, Zongyou,et al. Gefitinib for Epidermal Growth Factor Receptor Activated Osteoarthritis Subpopulation Treatment[J]. EBIOMEDICINE,2018,32(1):223-233. |
APA | Sun, Heng.,Wu, Yan.,Pan, Zongyou.,Yu, Dongsheng.,Chen, Pengfei.,...&Zou, Weiguo.(2018).Gefitinib for Epidermal Growth Factor Receptor Activated Osteoarthritis Subpopulation Treatment.EBIOMEDICINE,32(1),223-233. |
MLA | Sun, Heng,et al."Gefitinib for Epidermal Growth Factor Receptor Activated Osteoarthritis Subpopulation Treatment".EBIOMEDICINE 32.1(2018):223-233. |
个性服务 |
查看访问统计 |
相关权益政策 |
暂无数据 |
收藏/分享 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论